{"id":904075,"date":"2025-11-03T08:54:35","date_gmt":"2025-11-03T13:54:35","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/"},"modified":"2025-11-03T08:54:35","modified_gmt":"2025-11-03T13:54:35","slug":"foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/","title":{"rendered":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p>CAMBRIDGE, Mass., Nov.  03, 2025  (GLOBE NEWSWIRE) &#8212; Foghorn<sup>\u00ae<\/sup> Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.<\/p>\n<p>\n        <strong>Guggenheim Second Annual Healthcare Innovation Conference<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET<\/li>\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<li>Management will also participate in one-on-one meetings<\/li>\n<\/ul>\n<p>\n        <strong>Stifel 2025 Healthcare Conference<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Presentation: Thursday, November 13, 2025, at 4:00 p.m. ET<\/li>\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<li>Management will also participate in one-on-one meetings<\/li>\n<\/ul>\n<p>\n        <strong>Jefferies 2025 London Healthcare Conference<\/strong>\n      <\/p>\n<ul type=\"disc\">\n<li>Fireside Chat: Wednesday, November 19, 2025, at 10:30 a.m. GMT<\/li>\n<li>Presenter: Adrian Gottschalk, President and Chief Executive Officer<\/li>\n<li>Management will also participate in one-on-one meetings<\/li>\n<\/ul>\n<p>A webcast of the available presentations can be accessed under \u201cEvents &amp; Presentations\u201d in the Investors section of the Company\u2019s website, www.foghorntx.com, and will be available for 90 days.<\/p>\n<p align=\"justify\">\n        <strong>About Foghorn Therapeutics<\/strong><br \/>\n        <br \/>Foghorn<sup>\u00ae<\/sup> Therapeutics is discovering and developing a novel class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Through its proprietary scalable Gene Traffic Control<sup>\u00ae<\/sup> platform, Foghorn is systematically studying, identifying, and validating potential drug targets within the chromatin regulatory system. The Company is developing multiple product candidates in oncology. Visit our website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=iJszzAitts134uikVnZbIQWI92svu86cYFA6ugxYU171qEXPMx4rBxDCr4jh7P6ZcF3Y56GslFjJ6AR1V_DpwtE7ytnf4UvQbKfYyAoQ8BlVvU7e19kcoV-H9bJU2RKTNhUqL3F2CHYEDvDqqU2YuEmO15NpH8jlgI4oAAHacTU_TQ9M6_PzwG3OC4FlZZowNJvGy5w6Um1swQVpxgyUjXaxT3kBONadRrQZVo5-8qxA6DgrGtR8nVNF2wpi7EZbM1b-fv5pYtLaLvE8oQlEZA==\" rel=\"nofollow\" target=\"_blank\">www.foghorntx.com<\/a>\u00a0for more information on the Company, and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5cOtFi3HYs0pDU9aPUfekjv6g0nGF7fkbNoNe15pWGOMfTCw2qe-KrSq2Y9y_S443lDYSgzSEZQUJWc2uvvTy66ms_Q_V1xOH_0iDvumV5pHXz76nO0QPNj5Ff9rWqD0qfpGCVIQkdl065jFUCyxup3kvV9FaktUhbSayfb6RAsPSWrn2udBpzKNL47SLzR3iJPT-GZbmxqgkddczR6kyQ==\" rel=\"nofollow\" target=\"_blank\">X<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9TdrYezDlH6oBUf4WdA30NQqqKWYDhhUSQAX9CMRjXWULo_udBz6vippfrvs2S4WQLUwk8XySrucWlj1Bp-aaZ5IsvqgHna0EjW4hQy_wNp9blZCMYh7kmXKNaB6KQVEtBVUYIexGTd7RBQ00bfI0eRWiDLNIcpe1FPcok0Z0rrAcNCDiUI1N-jVolZkhDiXVP6PrW8VOehOZR6iObyL580VR0CGa1Vnvwq-7E02dYDDRNnaQWPFwUdHnLdaQ9uxTYJpWBovax2JvUdC7H1DRA==\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>.<\/p>\n<p>\n        <strong>Contact:<\/strong><br \/>\n        <br \/>Karin Hellsvik, Foghorn Therapeutics Inc.<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wRE0EIy5yD7PqMmTralHAZRgwibpR3leB3EmjWelHnk5mG-wVFpZ4q_lwUC-Z3WMYWOKm47a3WS6kEO8cp1vGR59pMx5RrDPqh_Gp9hvZyM=\" rel=\"nofollow\" target=\"_blank\">khellsvik@foghorntx.com<\/a><\/u><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/ZjZkMTQzODMtNjRhOC00ZDgyLWI0OTgtZDUxMDYwYzEwOTM0LTEyMTQ0MTUtMjAyNS0xMS0wMy1lbg==\/tiny\/Foghorn-Therapeutics-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Guggenheim Second Annual Healthcare Innovation Conference Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET Presenter: Adrian Gottschalk, President and Chief Executive Officer Management will also participate in one-on-one meetings Stifel 2025 Healthcare &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-904075","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Guggenheim Second Annual Healthcare Innovation Conference Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET Presenter: Adrian Gottschalk, President and Chief Executive Officer Management will also participate in one-on-one meetings Stifel 2025 Healthcare &hellip; Continue reading &quot;Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-11-03T13:54:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences\",\"datePublished\":\"2025-11-03T13:54:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/\",\"name\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\",\"datePublished\":\"2025-11-03T13:54:35+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/","og_locale":"en_US","og_type":"article","og_title":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk","og_description":"CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) &#8212; Foghorn\u00ae Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that management will participate in the Guggenheim Second Annual Healthcare Innovation Conference, Stifel 2025 Healthcare Conference, and Jefferies 2025 London Healthcare Conference. With an initial focus in oncology, Foghorn\u2019s Gene Traffic Control\u00ae\u00a0platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. Guggenheim Second Annual Healthcare Innovation Conference Fireside Chat: Monday, November 10, 2025, at 11:00 a.m. ET Presenter: Adrian Gottschalk, President and Chief Executive Officer Management will also participate in one-on-one meetings Stifel 2025 Healthcare &hellip; Continue reading \"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-11-03T13:54:35+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences","datePublished":"2025-11-03T13:54:35+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/","name":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=","datePublished":"2025-11-03T13:54:35+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTU2NjU2NyM3MjM3Njc1IzIyMDI4NjI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/foghorn-therapeutics-to-participate-in-three-upcoming-investor-conferences-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904075","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=904075"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/904075\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=904075"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=904075"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=904075"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}